Loading…
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,002 other S bills in the 113th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (16)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2014 · first_quarter · Medicare/Medicaid
Average Sales Price (H.R. 800, H.R. 1416, S. 806) PPACA Implementation (PL 111-148) CMS - (Sunshine, AMP and NADAC) SGR (H.R. 2810, S. 1871) Medicare Extenders (H.R. 3402) Centers For Medicare and Medicaid Services (Sunshine, AMP and NADAC)
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Medicare/Medicaid
Average Sales Price (H.R. 800, H.R. 1416, S. 806) PPACA Implementation (PL 111-148) CMS - (Sunshine, AMP and NADAC) SGR (H.R. 2810, S. 1871) Medicare Extenders (H.R. 3402) Centers For Medicare and Medicaid Services (Sunshine, AMP and NADAC)
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Medicare/Medicaid
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: $420,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Pharmacy
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. S. 1277, S. 1657, H.R. 3392 & H.R. 4096 legislation to prevent and reduce prescription drug abuse. H.R. 4190, Provide for coverage under Medicare program of pharmicist services
Client expense: $420,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
HR 800 S 806 -- Amends Part B (Supplementary Medical Insurance) of Title XVIII (Medicare) of the Social Security Act to exclude from the average sales price in calculating Medicare payments for drugs and biologicals any customary prompt pay discounts from manufacturers to wholesalers. HR 2869 - To amend Title XVIII of the Social Security Act to establish payment parity under the Medicare program for ambulatory cancer care services furnished in the hospital outpatient department and the physician office setting.
Client expense: Not reported · Firm income: $13,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| OH |
2014 · fourth_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act. H.R. 2869 "Medicare Patient Access to Cancer Treatment Act of 2013" H R 4302 "Protecting Access to Medicare Act of 2014" (PL 113-93) S.806/H.R.800 "To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare"
Client expense: $338,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
S. 806, H.R. 800 & H.R. 1416 relating to Average Sales Price
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
Medicare Part B Monitored CY13 & 14 Physician Fee Schedule for Neurologists Monitored Prompt Pay Legislation, H.R. 800 & S. 806 Monitored Implementation of the Medicare IVIG Access Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
**see addendum pageAverage Sales Price (H.R. 800, H.R. 1416, S. 806) PPACA Implementation (PL 111-148) SGR (H.R. 2810, S. 1871) Centers For Medicare and Medicaid Services (Sunshine, AMP and NADAC)
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 8; H.R. 800; S. 806; H.R.1416; H.R. 4709
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: $570,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
H.R.800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R.1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R.4709, S.1277, S.1657, H.R.3392, H.R.4096 & S. 2862 legislation to prevent and reduce prescription drug abuse. H.R. 4190, Provide for coverage under Medicare program of pharmicist services
Client expense: $570,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
(H.R.800/S. 806) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction). Sustainable Growth Rate.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
H.R.800 & S.806 Medicare Prompt Pay Discount Exclusion (H.R.800 & S.806), legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Cancer Patient Protection Act of 2013 (H.R.1416), legislation to exclude cancer drugs from sequestration cuts. Prescription Drug Abuse Legislation (H.R.1919, H.R.3204, S.957 & S.959)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
Average Sales Price (H.R. 800, H.R. 1416, S.806); PPACA Implementation (PL 111-148); Sustainable Growth Rate (S. 1871 and H.R. 2810); Centers for Medicare and Medicaid Services (Sunshine, AMP and NADAC)
Client expense: $257,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Medicare/Medicaid
Cancer Patient Protection Act of 2013 (HR 1425) to stop the Medicare sequester cut from being applied to payment for cancer drugs. Correcting a technical problem with Medicare reimbursement for cancer drugs (inclusion of wholesaler-to-manufacturer prompt pay discounts in the calculation of Medicare ASP-based reimbursement rates) (HR800 & S806). General fix to the Medicare SGR-based physician reimbursement system. Payment reform for cancer care. Problems with the 340B drug discount program. Payment parity between community cancer clinics and outpatient hospital departments.
Client expense: $82,085 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
Medicare Part B Monitored CY13 & 14 Physician Fee Schedule for Neurologists Monitored Prompt Pay Legislation, H.R. 800 & S. 806 Monitored Implementation of the Medicare IVIG Access Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medicare/Medicaid
HR800/S806 - Amends part B (Supplementary Medical Insurance) of title XVIII (Medicare) of the Social Security Act to exclude from the average sales price in calculating Medicare payments for drugs and biologicals any customary prompt pay discounts from manufacturers to wholesalers. HR2869 - To amend title XVIII of the Social Security Act to establish payment parity under the Medicare program for ambulatory cancer care services furnished in the hospital outpatient department and the physician office setting. Opposition to proposed Medicare cuts to radiation oncology services due to removal of radiation treatment vault as a direct practice expense input. No specific legislation.
Client expense: Not reported · Firm income: $13,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medicare/Medicaid
HR 800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure ore appropriate general payment amount for drugs and biological under Part B of the Medicare program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Cancer Patient Protection Act of 2013, legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medicare/Medicaid
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act. H.R. 2869 "Medicare Patient Access to Cancer Treatment Act of 2013" H R 4302 "Protecting Access to Medicare Act of 2014" (PL 113-93) H.R. 1416 "Cancer Patient Protection Act of 2013"S.806/H.R.800 "To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare"
Client expense: $240,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · third_quarter · Medicare/Medicaid
(H.R.800/S. 806) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction). Sustainable Growth Rate.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
H.R.800 & S.806 Medicare Prompt Pay Discount Exclusion (H.R.800 & S.806), legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Cancer Patient Protection Act of 2013 (H.R.1416), legislation to exclude cancer drugs from sequestration cuts. Prescription Drug Abuse Legislation (H.R.1919, H.R.3204, S.957 & S.959)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medicare/Medicaid
Medicare Part B Monitored CY13 & 14 Physician Fee Schedule for Neurologists Monitored Prompt Pay Legislation, H.R. 800 & S. 806 Monitored Implementation of the Medicare IVIG Access Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
H.R.800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R.1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R.4709, S.1277, S.1657, H.R.3392, H.R.4096 & S. 2862 legislation to prevent and reduce prescription drug abuse. H.R. 4190, Provide for coverage under Medicare program of pharmicist services
Client expense: $360,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medicare/Medicaid
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: $360,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medicare/Medicaid
Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 8; H.R. 800; S. 806; H.R.1416; H.R. 4709
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medicare/Medicaid
Average Sales Price (H.R. 800, H.R. 1416, S. 806); PPACA Implementation (PL 111-148);Sustainable Growth Rate (S. 1871 and H.R. 2810); Centers for Medicare and Medicaid Services (Sunshine, AMP and NADAC); The Protecting Access to Medicare Act of 2014 (H.R. 4302)
Client expense: $361,413 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · third_quarter · Medicare/Medicaid
Average Sales Price (H.R. 800, H.R. 1416, S. 806); PPACA Implementation (PL 111-148);Sustainable Growth Rate (S. 1871 and H.R. 2810); Centers for Medicare and Medicaid Services (Sunshine, AMP and NADAC); The Protecting Access to Medicare Act of 2014 (H.R. 4302)
Client expense: $361,413 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · third_quarter · Medicare/Medicaid
**see addendum pageAverage Sales Price (H.R. 800, H.R. 1416, S. 806) PPACA Implementation (PL 111-148) SGR (H.R. 2810, S. 1871) Protecting Access to Medicare Act of 2014 (H.R. 4302) Centers For Medicare and Medicaid Services (Sunshine, AMP and NADAC)
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Medicare/Medicaid
S. 806, H.R. 800 & H.R. 1416 relating to Average Sales Price
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
pharmaceutical and health care product distribution issues, Medicare Part B and D issues, Medicaid pharmacy issues, HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014.
Client expense: Not reported · Firm income: $15,000
2014 · third_quarter · Pharmacy
HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014
Client expense: Not reported · Firm income: $15,000
2014 · third_quarter · Pharmacy
HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014
Client expense: Not reported · Firm income: $7,500
2014 · third_quarter · Health Issues
pharmaceutical and health care product distribution issues, Medicare Part B and D issues, Medicaid pharmacy issues, HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014.
Client expense: Not reported · Firm income: $7,500
2014 · second_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act. H.R. 2869 "Medicare Patient Access to Cancer Treatment Act of 2013" H.R. 1416 "Cancer Patient Protection Act of 2013" H.R. 4302 "Protecting Access to Medicare Act of 2014" (PL 113-93)S.806/H.R. 800 To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · second_quarter · Pharmacy
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Medicare/Medicaid
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act. H.R. 2869 "Medicare Patient Access to Cancer Treatment Act of 2013" H.R. 1416 "Cancer Patient Protection Act of 2013" H.R. 4302 "Protecting Access to Medicare Act of 2014" (PL 113-93)S.806/H.R. 800 To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · second_quarter · Medicare/Medicaid
Medicare Part B Monitored CY13 & 14 Physician Fee Schedule for Neurologists Monitored Prompt Pay Legislation, H.R. 800 & S. 806 Monitored Implementation of the Medicare IVIG Access Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Medicare/Medicaid
H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: $350,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Pharmacy
H.R.800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R.1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. H.R.4709, S.1277, S.1657, H.R.3392 & H.R.4096 legislation to prevent and reduce prescription drug abuse.H.R. 4190, Provide for coverage under Medicare program of pharmicist services
Client expense: $350,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Medicare/Medicaid
Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 8; H.R. 800; S. 806; H.R.1416; H.R. 4709
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Medicare/Medicaid
(H.R.800/S. 806) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction). Sustainable Growth Rate.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Pharmacy
H.R.800 & S.806 Medicare Prompt Pay Discount Exclusion (H.R.800 & S.806), legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Cancer Patient Protection Act of 2013 (H.R.1416), legislation to exclude cancer drugs from sequestration cuts. Prescription Drug Abuse Legislation (H.R.1919, H.R.3204, S.957 & S.959)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Medicare/Medicaid
Passage of the Cancer Patient Protection Act of 2013 (H.R. 1416) to stop application of the Medicare sequester cut to cancer drugs; Passage of H.R. 800 & S. 806, identical bills to stop artificial reduction of Medicare reimbursement for cancer drugs due to inclusion of manufacturer-to-distributor prompt pay discounts in the calculation of reimbursement rates; House and Senate bills and legislative efforts to fix the Medicare reimbursement system based on the sustainable growth rate (SGR) and to reform the Medicare payment system; Passage of the Medicare Access to Cancer Treatment ACT (H.R 2869) to create site payment parity between community cancer clinics and outpatient hospitals for identical cancer care services.
Client expense: $86,065 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE